knowledge -WSS

knowledge

author：fashion 2025-08-12 11:30:05 - browse：3

Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.

For more on what we cover, here’s the news on Dewpoint Therapeutics; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Can food be medicine? And other questions about a new push

WSS

Hospitals look to new technology to keep health care workers safe

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Make 'food is medicine' a key part of White House nutrition meeting

Why is France rioting? What to know about the fatal police shooting of Nahel M

Morphosys mixed study results for blood cancer drug

Astellas still sees hope in its gene therapy after four deaths

focus

knowledge

explore

Psychedelics group wrestles with new pharma identity

Why is France rioting? What to know about the fatal police shooting of Nahel M

Hollywood unions extend contract negotiations for actors

In key trial, Verve's treatment lowers cholesterol levels in patients

Medical leaders decry Supreme Court decision on affirmative action

New case study details death in closely watched Alzhiemer's trial

BioMarin wins approval for gene therapy to treat hemophilia A

Option Care buys Amedisys in $3.6 billion home care deal

Trump demands the U.S. pay no more for drugs than other countries … again

Surge of respiratory disease in China has likely explanation

focus

Hospitals look to new technology to keep health care workers safe

Doctor appointment wait times are getting worse

Hospitals look to new technology to keep health care workers safe

World's first CRISPR

A new study asks: Are we harming blood donors by taking blood?

NYU radiologists take on the challenge of expensive MRI machines

focus

entertainment

explore

hotspot